

INFORMATION DISCLOSURE STATEMENT

Applicant : Roger Olsson
App. No : 10/568,149
Filed : February 10, 2006
For : 2-AMINOETHYL SUBSTITUTED PYRIMIDIN-
2-ONES, CYCLOPROPANES, PYRAZOLINES,
PYRIMIDINES AND BENZOTHAZEPINES
AND THEIR USES AS UROTENSIN II AND
SOMATOSTATIN 5 RECEPTOR LIGANDS

Examiner : Unknown
Art Unit : 1614

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 58 references to be considered by the Examiner. Also enclosed are 48 foreign patent references and non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 2/12/2007

By: 

Jeremy R. Pierce
Registration No. 59,034
Attorney of Record
Customer No. 20,995
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/568,149	
	Filing Date	February 10, 2006	
	First Named Inventor	Roger Olsson	
	Art Unit	1614	
SHEET 1 OF 4		Examiner	Unknown
		Attorney Docket No.	ACADIA.033NP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	2,683,742	07-13-1954	Cusic, et al.	
	2	2,793,212	05-21-1957	Pohland	
	3	2002/0193407 A1	12-19-2002	Kim et al.	
	4	3,096,329	07-02-1963	Steck et al.	
	5	3,401,166	09-10-1968	John Krapcho	
	6	3,467,675	09-16-1969	Petersen Povl Viggo et al.	
	7	3,880,885	04-29-1975	Houlihan William J. et al.	
	8	4,564,641	01-14-1986	Michael Alfred et al.	
	9	5,707,798	01-13-1998	Brann	
	10	6,605,623	08-12-2003	Ko et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	11	AU 503 490 B	09-06-1979	Sandoz AG		
	12	DE 20 15 544 A	10-08-1970	E.R. Squibb & Sons Inc.		
	13	DE 22 12 674 A	09-27-1973	Sandoz AG		
	14	EP 0 256 181 A1	02-24-1988	Nippon Chemiphar Co., Ltd.		
	15	FR 2 178 718 A	11-16-1973	Sandoz SA		
	16	FR 2 230 352 A	12-20-1974	Sandoz SA		
	17	GB 1 374 337 A	11-20-1974	Sandoz Ltd.		
	18	GB 1 419 681 A	12-31-1975	Sandoz Ltd.		
	19	GB 1 422 540 A	01-28-1976	Sandoz Ltd.		
	20	GB 1 471 455 A	04-27-1977	Sandoz Ltd.		
	21	JP 2004 203871 A	07-22-2004	Yamanouchi Pharma Co Ltd.		
	22	WO 2001/45711 A1	06-28-2001	Smithkline Beecham Corp.		

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/568,149
Filing Date	February 10, 2006
First Named Inventor	Roger Olsson
Art Unit	1614
Examiner	Unknown
Attorney Docket No.	ACADIA.033NP

(Multiple sheets used when necessary)

SHEET 2 OF 4

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	23	WO 2002/058702 A1	08-01-2002	SMITHKLINE BEECHAM CORPORATION		
	24	WO 2003/042178 A1	05-22-2003	ASTRAZENECA AB		
	25	WO 2003/048154 A1	06-12-2003	ACTELION PHARMACEUTICALS LTD.		
	26	WO 2003/104216 A1	12-18-2003	Acadia Pharmaceuticals Inc.		
	27	WO 2005/007656 A1	01-27-2005	VIROCHEM PHARMA INC.		
	28	WO 2005/030209 A1	04-07-2005	SMITHKLINE BEECHAM CORPORATION		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	29	BERTOZZI F. ET AL., "A Combinatorial Scaffold Approach Based Upon a Multicomponent Reaction," Organic Letters, Vol. 5, no. 9, May 1, 2003, pages 1551-1554.	
	30	Biochem. 11:942-944 (1972)	
	31	Bousette, N.; Patel, L.; Douglas, S. A.; Ohlstein, E. H.; Giaid, A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis (2004) 176, 117-123.	
	32	Bottrill et al., "Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries", Br. J. Pharmacol., 130(8); 1865-1870	
	33	Brauner-Osborne, H.; Brann, M. R. Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): High throughput assays in mammalian cells. Eur J Pharmacol 1996, 295, 93-102	
	34	Burstein, E. S.; BraunerOsborne, H.; Spalding, T. A.; Conklin, B. R.; Brann, M. R. Interactions of muscarinic receptors with the heterotrimeric G proteins G(q) and G(12): Transduction of proliferative signals. J Neurochem 1997, 68, 525-533	
	35	Burstein, E. S.; Piu, F.; Ma, J. N.; Weissman, J. T.; Currier, E. A.; Nash, N. R.; Weiner, D. M.; Spalding, T. A.; Schiffer, H. H.; Del Tredici, A. L.; Brann, M. R. Integrative Functional Assays, Chemical Genomics and High Throughput Screening: Harnessing Signal Transduction Pathways to a Common HTS Readout. Curr Pharm Des 2006, 12, 1717 - 1729	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/568,149
	Filing Date	February 10, 2006
	First Named Inventor	Roger Olsson
	Art Unit	1614
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 3 OF 4	Attorney Docket No.	ACADIA.033NP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	36	Burstein, E. S.; Spalding, T. A.; Brann, M. R. Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. <i>Mol Pharmacol</i> 1997, 51, 312-319	
	37	Chem. Abstr. 1998, 128-111548	
	38	Clark et al, "The urotensin II receptor is express in the cholinergic mesopontine tegmentum of the rat", <i>Brain Res.</i> (2001) 923:pages 120-127	
	39	Croston, G. E.; Olsson, R.; Currier, E. A.; Burstein, E. S.; Weiner, D.; Nash, N.; Severance, D.; Allenmark, S. G.; Thunberg, L.; Ma, J. N.; Mohell, N.; O'Dowd, B.; Brann, M. R.; Hacksell, U. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2-(dimethylamino)ethyl)isochroman-1-one. <i>J Med Chem</i> 2002, 45, 4950-4953.	
	40	Dhanak, D.; Neeb, M. J.; Douglas, S. A. Urotensin-II receptor modulators. <i>Annu Rep Med Chem</i> 2003, 38, 99-110	
	41	Douglas, S.; Aiyar, N. V.; Ohlstein, E. H.; Willette, R. N. Human urotensin-II, the most potent mammalian vasoconstrictor identified, represents a novel therapeutic target in the treatment of cardiovascular disease. <i>Eur Heart J</i> 2000, 21, 229-237	
	42	Douglas, S.; Dhanak, D.; Johns, D. G. From 'gills to pills': urotensin II as a regulator of mammalian cardiorenal function. <i>Trends in Pharmacological sciences</i> 2004, 25, 76 - 85	
	43	Fingl et al. 1975, in "The Pharmacological Basis of Therapeutics"	
	44	Flack, H. D. On Enantiomorph-Polarity Estimation. <i>Acta Crystallogr A</i> 1983, 39, 876-881	
	45	Gautier et al., "Reductions suivies de transformations dans l'ammoniac liquide. 5e memoire: reduction beta-alcoylation des chalcones" BULL. SOC. CHIM. FR., no. 12, 1969, pages. 4348-4355	
	46	Gibson et al., "Cardiovascular Effects of Urotension II in Anesthetized and Pithed Rats", <i>General and Comparative Endocrinology</i> 64; 435-439 (1986)	
	47	Greene and Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley & Sons, New York, NY, 1999	
	48	Hasegawa et al., ""Vasodepressor effects of urotensin II in rats", <i>Neuroendocrinol. Lett.</i> 14(5); 357-363, 1992	
	49	Huitron-Resendiz et al., "Urotensin II Modulates Rapid Eye Movement Sleep through Activation of Brainstem holinergic Neurons", <i>Journal of Neuroscience</i> (2005) 25:5465-54.	
	50	International Preliminary Examination Report for PCT/US03/18077 dated November 29, 2004	
	51	International Search Report and the Written Opinion for PCT/US2006/022337 dated December 28, 2006	
	52	International Search Report for PCT/US03/18077 dated September 29, 2003.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/568,149
	Filing Date	February 10, 2006
	First Named Inventor	Roger Olsson
	Art Unit	1614
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 4 OF 4	Attorney Docket No.	ACADIA.033NP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	53	International Search Report for PCT/US2004/004765 dated November 25, 2004.	
	54	Johns, D. G.; Ao, Z. H.; Naselsky, D.; Herold, C. L.; Maniscalco, K.; Sarov-Blat, L.; Steplewski, K.; Aiyar, N.; Douglas, S. A. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. <i>N-S Arch Pharmacol</i> 2004, 370, 238-250	
	55	Joyal, D.; Huynh, T.; Aiyar, N.; Guida, B.; Douglas, S.; Giaid, A. Urotensin-II levels in acute coronary syndromes. <i>Int J Cardiol</i> 2006, 108, 31-35	
	56	Kruger, S.; Graf, J.; Kunz, D.; Stickel, T.; Merx, M. W.; Hanrath, P.; Janssens, U. Urotensin II in patients with chronic heart failure. <i>Eur. J. Heart Fail.</i> (2005) 7, 475-478;	
	57	Kwarter, et al., "Some 4-Aminoquinoline and 9-Aminoacridine Derivatives", J. AM. CHEM. SOC., vol. 68, 1946, pages. 2395-2397	
	58	Langham, R. G.; Kelly, D. J.; Gow, R. M.; Zhang, Y.; Dowling, J. K.; Thomson, N. M.; Gilbert, R. E. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. <i>American Journal Of Kidney Diseases: The Official Journal Of The National Kidney Foundation</i> (2004) 44, 826-831).	

3397424
020707

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.